Staging primary melanoma

(No clinical nodal or metastatic disease)

BAUSSS VS TNM systems

BAUSSS is a method of predicting primary cutaneous melanoma outcomes using the six most valuable clinical and pathological predictors.

BAUSSS stands for **B**reslow thickness, **A**ge, **U**lceration, **S**ex, **S**ite and **S**ubtype

Table depicts **BRESLOW**, then **AGE** and then **ULCERATION**, as the three most valuable predictors
SEX Patient is male. Data for female patients show slightly reduced risk throughout.
SITE Location is head and neck. Trunk risk slightly higher. Limb risk slightly lower
SUBTYPE Figures pertain to superficial spreading or lentigo maligna type.
Risk increased with nodular melanoma and acral lentiginous melanoma

Cancer mortality 15-year risk % (**Validated with usage of LifeMath# with El Sharouni data@)

NOT ULCERATED				Breslow	ULCERATED			
20 y.o.	40 y.o.	60 y.o.	80 y.o.		20 y.o.	40 y.o.	60 y.o.	80 y.o.
0.6	1	1.4	1.9	0.2	1.4	2.5	3.4	4.7
1.2	2	2.8	3.8	0.4	2.8	4.9	6.7	9.1
1.8	3	4.7	5.7	0.6	4.2	7.2	9.8	13.3
2.3	4	5.5	7.5	0.8	5.6	9.5	12.9	17.3
2.9	5	6.9	9.3	1	6.9	11.7	15.9	21.2
3.5	6	8.2	11.1	1.2	8.2	13.9	18.7	24.9
4	6.9	9.5	12.8	1.4	9.5	16	21.5	28.3
4.6	7.9	10.8	14.5	1.6	10.8	18.1	24.2	31.7
5.2	8.8	12	16.2	1.8	12.1	20.1	26.7	34.9
5.7	9.7	13.3	17.8	2	13.3	22	29.2	37.9
6.3	10.7	14.5	19.4	2.2	14.6	24	31.6	40.8
6.8	11.6	15.7	21	2.4	15.8	25.8	33.9	43.5
7.4	12.5	16.9	22.5	2.6	17	27.6	36.2	46.2
7.9	13.4	18.1	24	2.8	18.2	29.4	38.4	48.7
8.5	14.2	19.2	25.5	3	19.3	31.2	40.5	51
9	15.1	20.4	26.9	3.2	20.5	32.9	42.5	53.3
9.5	16	21.5	28.3	3.4	21.6	34.5	44.4	55.5
10.1	16.8	22.6	29.7	3.6	22.7	36.1	46.3	57.6
10.6	17.7	23.7	31.1	3.8	23.8	37.7	48.1	59.5
11.1	18.5	24.8	32.4	4	24.9	39.2	49.9	61.4
12.4	20.6	27.4	35.7	4.5	27.5	42.9	54	65.8
13.7	22.6	29.9	38.7	5	30.1	46.3	57.9	69.6
15	24.6	32.4	41.7	5.5	32.6	49.6	61.3	73
16.2	26.5	34.7	44.5	6	34.9	52.6	64.5	76

TNM category labels overlaid on table: **T1a, T1b, T2a, T3a, T4a** (Not Ulcerated); **T1b, T2b, T3b, T4b** (Ulcerated)

Note the large variability of predicted outcomes per TMN category. BAUSSS refines patient risk prediction

**Validated by Global Melanoma Initiative

"Online prediction tools for melanoma survival: A comparison" Dixon et al. JEADV 2023
#http://www.lifemath.net/cancer/   @El Sharouni MA, Stodell MD, Ahmed T, et al. Ann Oncol 2021;32:375-383.